CONBRIZA

Nazione: Israele

Lingua: inglese

Fonte: Ministry of Health

Principio attivo:

BAZEDOXIFENE AS ACETATE 20 MG

Commercializzato da:

NEOPHARM LTD

Codice ATC:

G03XC02

Forma farmaceutica:

COATED TABLETS

Via di somministrazione:

PER OS

Prodotto da:

PFIZER IRELAND PHARMACEUTICALS

Gruppo terapeutico:

BAZEDOXIFENE

Indicazioni terapeutiche:

CONBRIZA is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. A significant reduction in the incidence of vertebral fractures has been demonstrated; efficacy on hip fractures has not been established. When determining the choice of CONBRIZA or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefit

Data dell'autorizzazione:

2013-04-01